Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
HO-1 and blocked the phosphorylations of IκB
the plasma clearance of EGFR-IN-2 is determined to be 104 mL/kg per min with a bioavailability of 19%
Tigemonam (0
which represents a new structural class of non-nucleoside antiviral drugs
CAS Number: 171746-21-7
Relugolix Catalog No.:M18801-C HO-1 and blocked the phosphorylationsRelugolix (TAK 385) is a potent, orally active, nonpeptidic gonadotropin releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0. 33 nM) and monkey receptor (IC50=0. 32 nM) compared with TAK 013 (HY 100209). Relugolix is used for the study of sex hormone dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al. Product information